Related Experiment Video
Updated: Aug 8, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Cell-based assays for profiling activity and safety properties of cancer drugs
Weiwei Li1, Marilyn S Lam, Andrew Birkeland
1Department of Pharmacology, Berlex Biosciences, Richmond, CA 94804, USA. wei-wei_li@berlex.com
Introduction:
Our goal was to establish versatile and high capacity assays to characterize activity and toxicity of chemotherapeutics. The major anti-cancer activity indicators of these agents included inhibition of proliferation and induction of apoptosis to cancer cells. In addition, cytotoxicity and myelosuppressive activity to normal cells were parameters to evaluate toxicity of these drugs.
Methods:
Using a panel of cell-based assay systems, we investigated activity and toxicity properties of selected cancer drugs. Drug effects on a number of normal and cancer cell types from human origin were evaluated.
Results:
Topoisomerase inhibitors (camptothecin, doxorubicin and etoposide) and microtubule inhibitors (colchicine and paclitaxel) showed anti-proliferation activity and induced apoptosis in MDA-231 cancer cells. Except for doxorubicin, these drugs had relatively low toxicity to normal cells because the dosage required for cytotoxicity EC(50) was >200-folds higher than the dosage for anti-proliferation EC(50) in cancer cells (MDA-231, HL60). However, these drugs were potent inducers of myelotoxicity in human bone marrow progenitor cells. In comparison, the DNA alkylating agents (cisplatin and carboplatin) were less potent proliferation inhibitors (EC(50)>10 microM) in MDA-231 cells and they were also less myelosuppressive.
Discussion:
Using marketed drugs as examples, our study established a multiple assay platform for profiling in vitro properties of cancer drugs. In drug discovery, such a platform will help to expedite lead selection at early stage.
Insights
This study developed a versatile assay platform to evaluate cancer drug activity and toxicity. It found that while some chemotherapy agents effectively inhibit cancer cell proliferation and induce apoptosis, they can also cause significant myelotoxicity in normal cells.
Area of Science:
- Pharmacology
- Cancer Biology
- Drug Discovery
Background:
- Chemotherapeutics are crucial in cancer treatment, necessitating robust methods to assess their efficacy and safety.
- Key indicators of anti-cancer drug activity include proliferation inhibition and apoptosis induction.
- Evaluating cytotoxicity and myelosuppression in normal cells is vital for understanding drug toxicity.
Purpose of the Study:
- To establish versatile, high-capacity assays for characterizing chemotherapeutic activity and toxicity.
- To investigate the activity and toxicity profiles of selected cancer drugs using cell-based assay systems.
- To compare the effects of different drug classes on cancer and normal human cells.
Main Methods:
- Utilized a panel of cell-based assay systems to evaluate drug effects.
- Assessed inhibition of proliferation and induction of apoptosis in cancer cells (MDA-231).
- Determined cytotoxicity in normal cells and myelotoxicity in human bone marrow progenitor cells.
Main Results:
- Topoisomerase and microtubule inhibitors demonstrated anti-proliferation and apoptosis-inducing activity in MDA-231 cancer cells.
- These agents exhibited low cytotoxicity to normal cells but were potent inducers of myelotoxicity.
- DNA alkylating agents (cisplatin, carboplatin) were less potent proliferation inhibitors and less myelosuppressive compared to other drug classes.
Conclusions:
- A multiple assay platform was established for profiling in vitro properties of cancer drugs using marketed examples.
- This platform aids in expediting lead selection during early-stage drug discovery.
- The findings highlight the differential toxicity profiles of various chemotherapy drug classes, particularly concerning myelosuppression.
